{"id":"b2b18584-6fed-4166-bedf-cfa7b899526b","modelId":"b1b7a2ef-267c-4571-a478-e999c75a5560","versionId":null,"locationId":"77331efb-55f0-4508-95db-bfdadf3a9543","operatorId":null,"ownerId":null,"slug":"sync-mt-sinai-new-york","status":"operational","firstSeen":"2021-01-01T00:00:00.000Z","statusChangeReason":null,"contractType":null,"pilotOutcome":null,"endedAt":null,"unitsOnSite":null,"tasksPerformed":null,"shiftStructure":null,"hoursPerDay":null,"siteType":null,"operatorConfirmed":null,"humanSupervisionOnsite":null,"locationPrecisionTier":null,"deploymentScale":null,"siteEnvironment":null,"operatorType":null,"sourceQualityTier":null,"manufacturerSerial":null,"reviewStatus":"reviewed","sources":[{"url":"https://evtoday.com/news/synchrons-brain-computer-interface-evaluated-in-command-early-feasibility-study","name":"EV Today","title":"Synchron's BCI Evaluated in COMMAND Study"}],"notes":"Mount Sinai Hospital, New York — COMMAND and INTENT trial site for Synchron Stentrode BCI. Enrolling patients with severe chronic bilateral upper-limb paralysis.","keyFacts":[],"reviewNote":null,"exposureHours":null,"deploymentMilesEstimate":null,"exposureBasis":null,"customerSegment":null,"scaleTier":null,"contractValueUsd":null,"contractValueBasis":null,"customerCompanyId":null,"customerExternalName":null,"createdAt":"2026-08-14T13:35:39.786Z","updatedAt":"2026-08-14T13:35:40.171Z","model":{"id":"b1b7a2ef-267c-4571-a478-e999c75a5560","companyId":"ac5afad9-cfd5-4b66-aa18-4d3aacf16560","modelName":"Synchron Stentrode","slug":"synchron-stentrode","description":"The Synchron Stentrode is an endovascular brain-computer interface implant that does not require open-brain surgery. Implanted via the jugular vein, it detects brain signals to enable patients with severe paralysis (ALS) to communicate via thought. The Stentrode has been tested in COMMAND (US) and SWITCH (Australia) clinical trials with no serious device-related adverse events.","formFactor":"wearable","industryVertical":null,"environment":null,"maturityStage":"pilot","lifecycleState":"active","supersededByModelId":null,"specs":{},"manufacturerSerial":null,"reviewStatus":"reviewed","sources":[{"url":"https://evtoday.com/news/synchrons-brain-computer-interface-evaluated-in-command-early-feasibility-study","title":"Synchron's BCI Evaluated in COMMAND Study","sourceName":"EV Today"}],"aliases":[],"collisionRisk":"low","reviewNote":null,"manufacturerTermForTeleop":null,"keyFacts":[{"label":"CEO","value":"Tom Oxley (Founder, neurologist, Mount Sinai)"},{"label":"Total funding","value":"over $345M ($200M Series D 2024, $75M Series C 2022)"},{"label":"Product","value":"Stentrode (endovascular BCI implant, no open-brain surgery)"},{"label":"Clinical trials","value":"COMMAND (US, FDA-approved), SWITCH (Australia, 4 patients)"},{"label":"Safety","value":"No serious device-related adverse events in 6 patients"},{"label":"Target","value":"Patients with severe paralysis (ALS) to communicate via thought"}],"createdAt":"2026-07-06T06:57:53.960Z","updatedAt":"2026-07-08T20:02:15.945Z","unitsInFieldClaimed":null,"unitsInFieldVerified":null,"unitsManufacturedClaimed":null,"unitsManufacturedVerified":null,"unitsAsOf":null,"unitsSource":null,"salesModel":null,"priceUndisclosedSince":null,"autonomyClass":null,"autonomyStatement":null,"autonomyStatementSource":null,"demoForensics":null,"exportControlClass":null,"minCommitment":null,"warrantyTerms":null,"serviceModel":null,"productionRateClaimed":null,"productionRateEvidenced":null,"teleopRatioDisclosed":null,"interventionRateDisclosed":null,"company":{"id":"ac5afad9-cfd5-4b66-aa18-4d3aacf16560","name":"Synchron","slug":"synchron","description":"Synchron is a brain-computer interface (BCI) company developing the Stentrode, a stentrode-based BCI implant that does not require open-brain surgery. Founded by neurologist Tom Oxley, the company has raised over $345M in total funding including a $200M Series D in 2024. Synchron's COMMAND and SWITCH clinical trials demonstrated no serious device-related adverse events across 6 patients, and the FDA has approved the Stentrode for early feasibility studies. The company is based in New York with origins in Melbourne, Australia.","status":null,"founded":2016,"hq":"New York, NY, USA","hqLat":40.7127281,"hqLng":-74.0060152,"hqGeocodedAt":"2026-08-05T14:50:15.330Z","hqAddress":null,"hqPrecision":null,"website":"synchrony.com","fundingTotal":"200000000","type":"hardware","reviewStatus":"reviewed","lifecycleState":"active","supersededByCompanyId":null,"sources":[{"url":"https://www.facebook.com/synchroninc/videos/-big-news-fda-approval-granted-for-synchrons-intent-trial-the-intent-trial-will-/2984514821739037/","title":"FDA approval granted for Synchron INTENT trial","sourceName":"Synchron"}],"keyFacts":[{"label":"CEO","value":"Tom Oxley (Founder, neurologist, Mount Sinai)"},{"label":"Total funding","value":"over $345M ($200M Series D 2024, $75M Series C 2022)"},{"label":"Product","value":"Stentrode (endovascular BCI implant, no open-brain surgery)"},{"label":"Clinical trials","value":"COMMAND (US, FDA-approved), SWITCH (Australia, 4 patients)"},{"label":"Safety","value":"No serious device-related adverse events in 6 patients"},{"label":"Target","value":"Patients with severe paralysis (ALS) to communicate via thought"}],"aliases":[],"collisionRisk":"low","reviewNote":null,"atsProvider":null,"atsSlug":null,"factoryLocations":null,"manufacturingCapacity":null,"orgType":null,"burnSignal":null,"litigationEvents":null,"insurancePostureDisclosed":null,"unitEconomicsDisclosed":null,"tickerSymbol":null,"stockExchange":null,"secCik":null,"revenueUsd":null,"revenueBasis":null,"revenueAsOf":null,"employeeCount":null,"employeeCountBasis":null,"employeeCountAsOf":null,"marketCapUsd":null,"marketCapAsOf":null,"marketCapSource":null,"createdAt":"2026-07-06T06:54:46.200Z","updatedAt":"2026-08-05T14:52:40.652Z"}},"version":null,"location":{"id":"77331efb-55f0-4508-95db-bfdadf3a9543","name":"New York, New York, USA","slug":"new-york-new-york-usa-6","kind":"hospital","parentLocationId":null,"region":null,"lat":null,"lng":null,"reviewStatus":"reviewed","aliases":[],"collisionRisk":"high","reviewNote":null,"createdAt":"2026-08-14T13:35:39.383Z","updatedAt":"2026-08-14T16:09:25.839Z"},"operator":null,"owner":null,"derived":{"trustTier":"unverified","currentPosture":null},"jsonLd":{"@context":"https://schema.org","@type":"Event","@id":"https://registry.deploy.report/deployments/sync-mt-sinai-new-york","url":"https://registry.deploy.report/deployments/sync-mt-sinai-new-york","name":"Synchron Stentrode at New York, New York, USA","identifier":"b2b18584-6fed-4166-bedf-cfa7b899526b","startDate":"2021-01-01T00:00:00.000Z","location":{"@type":"Place","@id":"https://registry.deploy.report/locations/new-york-new-york-usa-6","name":"New York, New York, USA"},"organizer":{"@type":"Organization","@id":"https://registry.deploy.report/companies/synchron","name":"Synchron"},"about":{"@type":"Product","@id":"https://registry.deploy.report/models/synchron-stentrode","name":"Synchron Stentrode"},"publisher":{"@id":"https://deploy.report/#organization"}},"framework_metadata":{"framework_schema_version":"0.1.0","verification_status":"verified","maturity_stage":"pilot","lifecycle_state":"active","architectural_position":{"cohort":"wearable","sub_cohorts":[]},"within_cohort_verified_vs_claimed_pair":null,"cap_flags":[],"verification_depth":{"sources_count":1,"primary_source_types":[]}}}